Personalis Stock Price, News & Analysis

Personalis, Inc. (NASDAQ: PSNL) is a health care company based in Fremont, California that focuses on advanced genomics for precision oncology. Classified within the medical laboratories industry, Personalis develops and provides personalized cancer testing designed to support the active management of cancer across the patient journey. The company emphasizes highly sensitive assays that combine tumor-and-normal profiling with proprietary algorithms to generate genomic insights as cancer evolves over time.

Personalis describes its products as being designed to detect minimal residual disease (MRD) and cancer recurrence at early timepoints, enable the selection of targeted therapies through ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. According to company disclosures, it generates revenue primarily from sequencing and data analysis services, including pharma tests and services, enterprise sales, population sequencing, and clinical diagnostic testing.

Business focus and core offerings

Personalis states that it is transforming the active management of cancer through breakthrough personalized testing. Its work centers on molecular residual disease testing and ultra-comprehensive genomic profiling to support both clinical care and biopharmaceutical research. The company’s assays are described as highly sensitive, using tumor-and-normal profiling and proprietary noise suppression algorithms to detect small traces of circulating tumor DNA (ctDNA) in blood samples.

The company identifies several key product lines and platforms in its materials. These include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions. NeXT Personal is highlighted as an ultra-sensitive, tumor-informed MRD assay designed to detect very low levels of ctDNA for monitoring residual or recurrent cancer and for assessing treatment response. Personalis also offers options such as Real-Time Variant Tracker, an extension to NeXT Personal that provides additional reporting on detected resistance and therapeutically targetable mutations during MRD monitoring.

Precision oncology and MRD specialization

Personalis repeatedly positions itself as a leader in advanced genomics for precision oncology and in ultrasensitive MRD testing. Its communications describe a focus on enabling physicians to guide care from biopsy through long-term surveillance, using molecular data to track cancer dynamics. The company reports that its NeXT Personal platform has been applied across solid tumors, including breast cancer and non-small cell lung cancer (NSCLC), and in immunotherapy settings.

Published data cited by Personalis include studies in journals such as Clinical Cancer Research and Cell. These studies describe the use of NeXT Personal to monitor ctDNA dynamics in patients with stage IV solid tumors treated with immunotherapy, and in stage I–III NSCLC within the TRACERx study. According to these publications, the assay has been used to detect ctDNA at baseline across multiple tumor types, to evaluate early ctDNA changes as prognostic indicators, and to monitor residual disease and relapse risk over extended surveillance periods.

Clinical applications and breast cancer surveillance

Personalis reports that its NeXT Personal test has received Medicare coverage for post-treatment surveillance of cancer recurrence in patients with stage II and III breast cancer. The coverage, described in both press releases and SEC filings, applies to recurrence monitoring in the surveillance setting for up to six years post-treatment, including major breast cancer subtypes such as HR+/HER2-, HER2+, and triple-negative breast cancer. The company notes that this coverage represents an important milestone for expanding access to ultrasensitive MRD testing in breast cancer.

In its announcements, Personalis references a study published in Annals of Oncology involving patients with triple-negative, HER2+, and HR+ breast cancers. The study is described as showing that NeXT Personal can detect very small traces of recurrent breast cancer from a blood test, with detections reported ahead of standard-of-care radiographic imaging and with negative tests associated with patients remaining disease-free during the study period.

Lung cancer and immunotherapy monitoring

Beyond breast cancer, Personalis highlights applications of NeXT Personal in lung cancer and broader immunotherapy contexts. In collaboration with academic and biopharma partners, the company reports data from the TRACERx study in NSCLC and from AstraZeneca’s clinical trials such as NeoADAURA and LAURA. These collaborations are described as demonstrating that ultrasensitive ctDNA monitoring can detect residual disease and recurrence earlier than imaging, stratify relapse risk, and monitor response to adjuvant or maintenance therapies.

In the TRACERx cohort, NeXT Personal was used to track NSCLC patients from diagnosis through long-term surveillance. Personalis reports that the assay detected ctDNA at very low levels, including in hard-to-detect subtypes, and that ctDNA detection at various timepoints was associated with relapse risk and overall survival. In the LAURA trial, Personalis states that NeXT Personal was used to assess maintenance treatment response in unresectable stage III EGFR-mutated NSCLC, with ctDNA-based MRD progression detected ahead of blinded imaging review.

Biopharma partnerships and research support

Personalis’ materials indicate that the company serves biopharmaceutical customers through pharma tests, services, and other research offerings. Revenue categories disclosed in financial statements include pharma tests and services, enterprise sales, population sequencing, and other revenue. The company references collaborations with organizations such as AstraZeneca and academic centers including Vall d’Hebron Institute of Oncology and Yale Cancer Center, where NeXT Personal is used in clinical trials and observational studies to generate biomarker and MRD data.

These collaborations are presented as supporting drug development by providing sensitive measures of treatment response, early indicators of recurrence, and insights into ctDNA dynamics across different therapies and tumor types. Personalis also notes that its technology has been used in large population sequencing efforts, such as the U.S. Department of Veterans Affairs Million Veterans Program, through which it has historically generated enterprise and population sequencing revenue.

Commercial strategy and market positioning

Personalis describes a commercial focus summarized as a "Win-in-MRD" strategy, emphasizing growth in clinical test volumes and physician adoption of NeXT Personal for cancer monitoring. Company communications report substantial year-over-year growth in clinical test volumes and highlight Medicare coverage decisions as catalysts for clinical revenue and market adoption in the MRD space. The company also notes a commercialization and reference laboratory agreement with Tempus AI, Inc., under which Tempus is authorized to market NeXT Personal in indications including breast cancer, lung cancer, immuno-oncology monitoring, and colorectal cancer, subject to specified terms and exclusivity periods.

Within its financial disclosures, Personalis identifies one primary segment focused on the sale of sequencing and data analysis services. It separates revenue into core streams such as pharma tests and services, enterprise sales, population sequencing, and clinical diagnostic revenue, reflecting both research-oriented and clinical applications of its genomics platforms.

Technology approach

Across its press releases and descriptions, Personalis emphasizes several technical aspects of its platforms. The company states that its assays use tumor-and-normal profiling, whole-genome sequencing, and proprietary noise suppression algorithms to detect ctDNA at very low levels, including what it describes as an ultrasensitive range. NeXT Personal is characterized as a tumor-informed assay that tracks large numbers of tumor-specific variants unique to each patient’s cancer, allowing for sensitive detection of residual disease and changes in ctDNA over time.

The Real-Time Variant Tracker option for NeXT Personal is presented as an additional reporting capability that identifies emerging or evolving therapy resistance mutations and therapeutically targetable mutations during MRD monitoring. Personalis notes that this option can report on mutations such as ESR1 in HR+/HER2- breast cancer and hundreds of other clinically relevant mutations in solid tumors, with availability through an early access program for clinical and academic users and for biopharma partners.

Regulatory and reimbursement context

Personalis’ SEC filings describe Medicare coverage determinations and reimbursement rates for NeXT Personal tests used in breast cancer recurrence surveillance. The company reports that the Centers for Medicare & Medicaid Services Molecular Diagnostics Program has established reimbursement rates for the NeXT Personal Dx Breast MRD Recurrence Monitoring Test and the NeXT Personal Single Plasma Test, with coverage parameters such as availability once per cancer diagnosis for certain tests and coverage for defined surveillance periods post-treatment.

These regulatory and reimbursement developments are highlighted by Personalis as important steps in supporting clinical adoption of its MRD testing in oncology practice. The company continues to report efforts to obtain Medicare coverage for additional indications, including lung cancer, and to expand the evidence base supporting its assays through clinical studies and publications.

Stock listing and corporate structure

According to SEC filings, Personalis’ common stock trades on The Nasdaq Global Market under the ticker symbol PSNL. The company reports itself as a corporation with common stock having a par value of $0.0001 per share and identifies itself as operating within the health care sector. Its filings include standard disclosures related to financial results, material agreements, and other corporate events.

FAQs about Personalis, Inc. (PSNL)